The American Journal of Managed Care

NPM1 MRD Status Is a Dominant Predictor of AML Relapse After AlloHCT

NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...
Medscape

MRD Status Predicts Transplant Benefit in NPM1-Mutated AML

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...
Medscape

AML: Monitor Early Measurable Residual Disease to Optimize Outcomes

Early clearance of measurable residual disease (MRD) after induction therapy in patients with acute myeloid leukemia (AML) is associated with significantly better relapse-free survival (RFS) than ...
The American Journal of Managed Care

MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS

MRD status before allo-HSCT is a strong prognostic factor for OS, DFS, and CIR in AML and MDS patients. MRD-negative patients showed significantly better OS and DFS compared to MRD-positive patients, ...
Seeking Alpha

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

– Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) – – 47% (30/64) ORR in a heavily pre-treated population, including 75% with prior ...